LAVA Therapeutics (LVTX) Competitors $1.31 -0.01 (-0.76%) Closing price 07/2/2025 03:56 PM EasternExtended Trading$1.34 +0.03 (+2.67%) As of 07/2/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LVTX vs. FATE, KYTX, BDTX, VXRT, LXEO, LYEL, BYSI, NMRA, NKTX, and FTLFShould you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), BeyondSpring (BYSI), Neumora Therapeutics (NMRA), Nkarta (NKTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. LAVA Therapeutics vs. Its Competitors Fate Therapeutics Kyverna Therapeutics Black Diamond Therapeutics Vaxart Lexeo Therapeutics Lyell Immunopharma BeyondSpring Neumora Therapeutics Nkarta FitLife Brands LAVA Therapeutics (NASDAQ:LVTX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Which has stronger earnings & valuation, LVTX or FATE? LAVA Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLAVA Therapeutics$11.98M2.88-$25.11M-$1.04-1.26Fate Therapeutics$13.63M9.42-$186.26M-$1.49-0.75 Which has more risk & volatility, LVTX or FATE? LAVA Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Is LVTX or FATE more profitable? LAVA Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat LAVA Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LAVA TherapeuticsN/A -86.38% -34.12% Fate Therapeutics -1,318.93%-47.17%-34.60% Do analysts rate LVTX or FATE? LAVA Therapeutics currently has a consensus target price of $3.17, indicating a potential upside of 141.73%. Fate Therapeutics has a consensus target price of $3.83, indicating a potential upside of 242.26%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Fate Therapeutics is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LAVA Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Does the media refer more to LVTX or FATE? In the previous week, Fate Therapeutics had 2 more articles in the media than LAVA Therapeutics. MarketBeat recorded 2 mentions for Fate Therapeutics and 0 mentions for LAVA Therapeutics. LAVA Therapeutics' average media sentiment score of 1.87 beat Fate Therapeutics' score of 0.65 indicating that LAVA Therapeutics is being referred to more favorably in the media. Company Overall Sentiment LAVA Therapeutics Very Positive Fate Therapeutics Positive Do institutionals & insiders hold more shares of LVTX or FATE? 97.5% of Fate Therapeutics shares are held by institutional investors. 9.5% of LAVA Therapeutics shares are held by insiders. Comparatively, 5.5% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryFate Therapeutics beats LAVA Therapeutics on 10 of the 16 factors compared between the two stocks. Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LVTX vs. The Competition Export to ExcelMetricLAVA TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.72M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-1.2621.3126.2219.90Price / Sales2.88278.47413.03113.66Price / CashN/A41.4736.1356.90Price / Book1.247.518.045.38Net Income-$25.11M-$55.05M$3.15B$248.50M7 Day Performance0.38%2.07%1.43%2.04%1 Month Performance-0.76%4.84%3.62%4.84%1 Year Performance-27.22%5.37%34.92%20.23% LAVA Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LVTXLAVA Therapeutics2.1048 of 5 stars$1.31-0.8%$3.17+141.7%-29.9%$34.72M$11.98M-1.2660Positive NewsGap UpFATEFate Therapeutics4.1011 of 5 stars$1.14-4.2%$3.83+236.3%-65.2%$136.38M$13.63M-0.77550Gap DownKYTXKyverna Therapeutics2.0782 of 5 stars$3.22+4.9%$18.50+474.5%-64.8%$132.68M$7.03M-0.9596News CoverageBDTXBlack Diamond Therapeutics3.2909 of 5 stars$2.27-2.6%$14.60+543.2%-38.2%$132.49MN/A37.8390Positive NewsAnalyst UpgradeVXRTVaxart2.3673 of 5 stars$0.56-3.4%$3.00+435.3%-35.4%$132.42M$28.70M-2.08120Positive NewsGap DownLXEOLexeo Therapeutics2.4974 of 5 stars$3.96+1.3%$16.60+319.2%-68.8%$129.80M$650K-1.2058News CoverageLYELLyell Immunopharma3.3299 of 5 stars$8.99+3.5%$20.00+122.5%-68.8%$128.68M$60K-0.36270BYSIBeyondSpringN/A$2.74-13.6%N/A-3.0%$127.80M$1.75M0.0080Positive NewsGap DownHigh Trading VolumeNMRANeumora Therapeutics2.593 of 5 stars$0.75-5.1%$9.29+1,144.7%-92.0%$127.08MN/A-0.46108News CoverageNKTXNkarta2.2621 of 5 stars$1.75-1.4%$14.33+721.4%-66.9%$125.60MN/A-1.16140News CoverageFTLFFitLife Brands4.387 of 5 stars$12.99-2.5%$20.50+57.8%-19.0%$125.09M$64.47M15.4620 Related Companies and Tools Related Companies Fate Therapeutics Alternatives Kyverna Therapeutics Alternatives Black Diamond Therapeutics Alternatives Vaxart Alternatives Lexeo Therapeutics Alternatives Lyell Immunopharma Alternatives BeyondSpring Alternatives Neumora Therapeutics Alternatives Nkarta Alternatives FitLife Brands Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LVTX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
